InvestorsHub Logo
Followers 53
Posts 4314
Boards Moderated 0
Alias Born 02/28/2010

Re: Riskreturn168 post# 100605

Sunday, 05/04/2014 1:30:06 PM

Sunday, May 04, 2014 1:30:06 PM

Post# of 130505
I still think one p.r. could double/triple the share price at any time. Even then it would still be below Napadano's .24 valuation.

Quest Diagnostics for LymPro makes the most sense. Johnson & Johnson could be a second choice.

Novartis for MANF for diabetes?

Twitter: @AmarantusBio .... 9,333 followers.

p.s. I still own 112,000 shares.